These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 895939)

  • 1. Some data concerning immune processes in concomitant tumor immunity experimental models. Comparative in vivo and in vitro investigation I. In vivo experiments.
    Badea E; Donovan G; Dumitrescu R; Fadel L; Popp I
    Neoplasma; 1977; 24(3):295-301. PubMed ID: 895939
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Some data concerning immune processes in concomitant tumor immunity experimental models. Comparative in vivo and in vitro investigations II. In vitro experiments.
    Donovan G; Popp I; Badea E; Bologa L
    Neoplasma; 1977; 24(3):303-10. PubMed ID: 895940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The specificity of concomitant tumor immunity at large tumor volumes.
    Deckers PJ; Pardridge DH; Wang BS; Mannick JA
    Cancer Res; 1976 Oct; 36(10):3690-4. PubMed ID: 953994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of concomitant and sinecomitant immunity on postsurgical metastasis in mice.
    Nomi S; Naito K; Kahan BD; Pellis NR
    Cancer Res; 1986 Dec; 46(12 Pt 1):6111-5. PubMed ID: 3779631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence for the functional binding in vivo of tumor rejection antigens to antigen-presenting cells in tumor-bearing hosts.
    Shimizu J; Zou JP; Ikegame K; Katagiri T; Fujiwara H; Hamaoka T
    J Immunol; 1991 Mar; 146(5):1708-14. PubMed ID: 1993850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Studies of allogeneic tumor transplants: induced rejection of advanced tumors by immune alteration of recipients.
    Russell PS; Chase CM; Burton RC
    J Immunol; 1983 Feb; 130(2):951-7. PubMed ID: 6336775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retardation of postsurgical metastases with the use of extracted tumor-specific transplantation antigens and cyclophosphamide.
    Nomi S; Pellis NR; Kahan BD
    J Natl Cancer Inst; 1984 Oct; 73(4):943-50. PubMed ID: 6237215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulation of murine tumor major histocompatibility antigens by cytokines in vivo and in vitro.
    Weber JS; Rosenberg SA
    Cancer Res; 1988 Oct; 48(20):5818-24. PubMed ID: 3139284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intracamerally induced concomitant immunity: mice harboring progressively growing intraocular tumors are immune to spontaneous metastases and secondary tumor challenge.
    Niederkorn JY; Streilein JW
    J Immunol; 1983 Nov; 131(5):2587-94. PubMed ID: 6415174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of the immunosuppressive drug niridazole in isogeneic and allogeneic mouse tumor systems in vivo.
    Deodhar SD; Lee VW; Chiang T; Mahmoud AF; Watten KS
    Cancer Res; 1976 Sep; 36(9 pt.1):3147-50. PubMed ID: 975080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The activity of regional nodes in the evolution of immune responses to allogeneic and isogeneic tumors.
    Barna B; Deodhar SD
    Cancer Res; 1975 Apr; 35(4):920-6. PubMed ID: 1116149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Defective function of Langerhans cells in tumor-bearing animals is the result of defective maturation from hemopoietic progenitors.
    Ishida T; Oyama T; Carbone DP; Gabrilovich DI
    J Immunol; 1998 Nov; 161(9):4842-51. PubMed ID: 9794417
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Participation of the immune system in regression of a rat Mc7 sarcoma by hyperthermia.
    Shah SA
    Cancer Res; 1981 May; 41(5):1742-7. PubMed ID: 7214341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulation of the immune response to tumor antigens. II. The nature of immunosuppressor cells in tumor-bearing hosts.
    Fujimoto S; Greene MI; Sehon AH
    J Immunol; 1976 Mar; 116(3):800-6. PubMed ID: 1254955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cellular interactions and the role of interleukin 2 in the expression and induction of immunity against a syngeneic murine sarcoma.
    Chou T; Shu S
    J Immunol; 1987 Sep; 139(6):2103-9. PubMed ID: 2957448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of covalently bound cord factor analog to increase tumor immunogenicity.
    Eggers AE; Tarmin L; Ginsburg S
    J Biol Response Mod; 1984 Aug; 3(4):413-22. PubMed ID: 6332882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Augmenting major histocompatibility complex class I expression by murine tumors in vivo enhances antitumor immunity induced by an active immunotherapy strategy.
    Merritt RE; Yamada RE; Crystal RG; Korst RJ
    J Thorac Cardiovasc Surg; 2004 Feb; 127(2):355-64. PubMed ID: 14762342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary chemically induced tumors induce profound immunosuppression concomitant with apoptosis and alterations in signal transduction in T cells and NK cells.
    Horiguchi S; Petersson M; Nakazawa T; Kanda M; Zea AH; Ochoa AC; Kiessling R
    Cancer Res; 1999 Jun; 59(12):2950-6. PubMed ID: 10383160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suppression of Moloney sarcoma virus immunity following sensitization with attenuated virus.
    Wood GW
    Cancer Res; 1976 Dec; 36(12):4552-7. PubMed ID: 1000500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor-specific immune responsiveness of the tumor-bearing host.
    Burk MW; Yu S; McKhann CF
    Isr J Med Sci; 1976; 12(4-5):360-8. PubMed ID: 939694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.